Drug
Palovarotene
Palovarotene: highest development phase Phase 2, developed by United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Palovarotene NCT02521792 | Phase 2 | Fibrodysplasia Ossificans Progressiva |
| Palovarotene NCT04829773 | Phase 1 | Fibrodysplasia Ossificans Progressiva |
| Palovarotene NCT04762355 | Phase 1 | Dry Eye Disease |
Latest
No recent events.
Follow Palovarotene on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.